USA flag logo/image

An Official Website of the United States Government

SBIR Phase II: Improved in Vivo Delivery of SiRNA

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
88210
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
0738167
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOO Scientific
7050 Burleson Rd. Austin, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: SBIR Phase II: Improved in Vivo Delivery of SiRNA
Agency: NSF
Contract: 0923854
Award Amount: $500,000.00
 

Abstract:

This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). This Small Business Innovation Research (SBIR) Phase II project will develop technologies that optimize the use of RNA interference (RNAi) in animals. RNAi is an invaluable tool for characterizing gene function and is a promising candidate for gene therapy. The use of RNAi in tissue culture is well developed but is of limited use in experimental animals. RNAi agents must enter cells to exert their effects but this has proven to be challenging in animals. The current lack of such technologies is holding back the majority of important RNAi animal experiments. To open this bottleneck, kits and reagents will be developed based on Bioo Scientific?s Targeted Transport Technology (T3). Easy-to-use RNAi delivery products will be manufactured, validated and commercialized for use in animal experiments. The broader impacts of this research are twofold. First, researchers will gain ready access to products that greatly simplify the use of RNAi in animals, thereby, stimulating a burst of validation experiments in animals to try to replicate prior results derived from tissue culture experiments. Animals are more complex than their tissue culture counterparts and it is uncertain that results can be duplicated in an animal. Second, T3 has the potential to be used for the therapeutic delivery of RNAi agents. In sum, this project will propel the validation of tissue culture results via T3 enabled animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the potential to deliver RNAi agents as drugs.

Principal Investigator:

Lance P. Ford
PhD
5127078993
lford@biooscientific.com

Business Contact:

Lance P. Ford
PhD
5127078993
lford@biooscientific.com
Small Business Information at Submission:

Bioo Scientific
3913 Todd Lane Suite 312 Austin, TX 78744

EIN/Tax ID: 870781699
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No